Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice

Kyung Tak Oh, Kyo Chul Koo, Byung Ha Chung, Kwang Suk Lee
Department of Urology, Yonsei University College of Medicine, Seoul, Korea

Purpose: Several strategies of prostate biopsy (PBx) have been introduced to improve prostate cancer (PCa) detection rates. However, studies comparing cancer detection rates (CDRs) according to biopsy methods in real-world practice are scarce. This study aimed to investigate CDRs according to the biopsy methods for patients with prostate-specific antigen (PSA) <10.0 ng/mL.

Materials and Methods: From 2006 to 2015, patients who underwent PBx were initially selected. All patients were categorized according to the biopsy methods performed (magnetic resonance imaging targeted biopsy [MR-TBx], 12+2 hypoechoic lesion target biopsy, saturation biopsy [sPBx], extended biopsy, and 12-core PBx). The CDR of MR-TBx was compared to that of sPBx and other protocols. Volume per core (VPC) was defined as prostate volume divided by the number of biopsy cores. Patients previously diagnosed with PCa were excluded.

Results: Of the 1,598 patients (median PSA, 5.41 ng/mL), 401 (25.1%) were diagnosed with PCa. Among the biopsy methods, MR-TBx has the highest CDR and proportion of Gleason score ≥7 (3+4). Biopsy methods, VPC, age, prostate volume, and PSA were associated with PCa detection. In the sub-analysis for initial biopsy, MR-TBx had no significant difference with sPBx, but had higher CDR than the other biopsy protocols. For repeat biopsy, VPC, rather than the biopsy method, was associated with CDR.

Conclusions: This study reaffirmed the efficacy of MR-TBx on CDR in real-world practice. In cases with barriers to performing magnetic resonance imaging, VPC might be useful for adjusting the optimal number of biopsy cores in repeat biopsy.

Keywords: Biopsy; Image-guided biopsy; Prostatic neoplasms

INTRODUCTION

Since the 6-core biopsy was introduced by Hodge et al. [1], the 10- to 12-core transrectal ultrasound (TRUS)-guided biopsy has become the standard diagnostic method [2]. To improve the efficacy of prostate biopsy (PBx), several biopsy methods, including saturation biopsy, extended biopsy, and advanced technology, such as multi-parametric magnetic resonance imaging (MRI), contrast-enhanced TRUS, and sono-elastography, were widely introduced [3,4]. Regarding biomarkers, percent-free prostate-specific antigen (PSA), prostate health index (PHI®; Beckman Coulter, Brea, CA, USA),
Outcomes of several biopsy modalities in practice

ExoDx® prostate intelliscore (EPI; Exosome Diagnostics, Boston, MA, USA), prostate cancer antigen 3 (PCA3; Progensa, Bedford, MA, USA), and so on have been investigated for patients with high PSA [5]. Especially, the National Comprehensive Cancer Network (NCCN) recommended to consider performing MRI or assessing biomarkers before PBx in suspicious prostate cancer (PCa) patients [6]. However, because of the additional costs, MRI or biomarkers might be only used for selected patients.

The increasing number of biopsy cores was generally considered to be used to facilitate higher cancer detection rate (CDR) in practice. To introduce the newly advanced biopsy technique, the outcomes in real-world practice, including the CDR, cost-efficacy, and risk of complication, were investigated. Furthermore, the outcomes of the advanced biopsy technique in real-world practice should be confirmed to be superior to those of the increasing number of biopsy cores. Although numerous papers have presented the results of experts, there are few studies that have analyzed CDRs according to the various biopsy methods in practice. Therefore, the aim of this study was to compare the CDRs of several biopsy methods for patients with PSA <10.0 ng/mL.

MATERIALS AND METHODS

1. Study population and data collection

Gangnam Severance Hospital Institutional Review Board approval was obtained for this study to collect data on all patients who had undergone PBx for suspicious PCa at our institution between January 2006 and December 2015 (approval number: 2019-0325-001), and informed consent was obtained from all individual participants included in the study. We reviewed 1,631 patients with PSA <10.0 ng/mL. A total of 33 biopsies were excluded from the study for the following reasons: 16 had received a prior diagnosis of PCa, 7 had received radiation treatment, 6 had underwent digit-guided PBx, and 4 were submitted for evaluation for extraperitoneal mass. Finally, 1,598 patients were included in the final analysis.

Patient characteristics included clinico-pathologic data, such as age at PBx, presence of previous biopsy history, prostate volume (PV), PSA, PSA density (PSA value divided by PV), volume per core (VPC: PV divided by the number of biopsy cores), and biopsy methods [7].

For calculating VPC, we hypothesized that the PBx cores were evenly inserted into the prostate tissue.

2. Indication and protocols of PBx

The indications for PBx were persistent clinical suspicions of PCa such as elevated PSA level ≥30 ng/mL, steadily increasing PSA levels, abnormal digital rectal examination, abnormal TRUS result, and abnormal pathologic finding including high-grade prostatic intraductal neoplasia or atypical small acinar proliferation of prostate with the prior PBx. We performed a PBx under local anesthesia with the BK Medical Flex Focus 500 ultrasound system (Analogic Corporation, Peabody, MA, USA) by using a 7.5 to 12 MHz multiplanar probe.

3. Stratifying biopsy methods

The standard biopsy methods for patients with suspicious PCa was 12-core PBx. To reduce the number of cases with unfortunately missed diagnosis of PCa, our institution introduced the prebiopsy MRI and several methods related to the increasing number of biopsy cores. Our target biopsy protocol for MRI targeted biopsy (MR-TBx) or hypoechoic lesion on TRUS consisted of 12-core PBx after target biopsy on suspicious lesions. MR-TBx with cognitive technique was performed by two urologists (L.K.S or L.D.H). A 12+2 hypoechoic lesion target biopsy (12+2HLTBx) was performed to evaluate the efficacy of hypoechoic lesions chosen by clinicians experienced in performing MR-TBx for cancer detection [8]. Patients who underwent additional biopsy cores on lesions with abnormal finding in TRUS were regarded as the extended biopsy group. Finally, biopsy methods were categorized into 5 groups (MR-TBx, 12+2HLTBx, 24-core saturation biopsy (sPBx), extended biopsy, and 12-core PBx).

However, 12+2HLTBx was not considered as the generalized methods. To analyze the efficacy of MR-TBx, we compared the CDRs among MR-TBx, sPBx, and other protocols with the possibility to improve the CDR in practice (12+2HLTBx, extended biopsy, and 12-core PBx).

4. MRI protocol and image analysis

For MR-TBx, all patients underwent imaging using a 30T MRI system (Intera Achieva 30T; Phillips Medical System, Best, The Netherlands) equipped with a phased array coil (6 channels). All patients underwent diffusion weighted imaging MRI and dynamic contrast enhanced MRI in addition to the routine prostate MRI protocol of 3 orthogonal planes (axial, sagittal, and coronal) used at our institution. Two b values (0, 1,000) were used, and diffusion restriction was quantified through apparent diffusion coefficient mapping. All images were reviewed by 2 experienced uro-radiologists who were blinded to the biopsy results.

5. Statistical analysis

Continuous variables were expressed as the mean±
standard deviation). Categorical variables were reported as the number of occurrences and frequency. The Pearson’s chi-squared test was used for statistical comparisons of continuous and categorical variables. Univariate and multivariate logistic regression analyses were carried out using clinical parameters. Variables that were found to be significant in the univariate analyses (p<0.05) were entered into the multivariate analysis. Receiver operating characteristic (ROC) curves and area under the ROC curves (AUCs) were used to obtain the cut-off value. The optimal cut-off value of VPC was determined using Youden’s index (sensitivity+specificity-1). The optimal cut-off values were based on predefined values and according to a sensitivity analysis using Youden index. Statistical analyses were performed using the IBM SPSS Statistics version 23.0 for Windows (IBM Corp., Armonk, NY, USA). All tests were two-sided and performed at the 5% significance level.

RESULTS

The patient characteristics are shown in Table 1. Of the 1,598 patients, 401 (25.1%) were diagnosed with PCa. The mean age of the groups with and without PCa were 66.8 and 63.3 years, respectively (p<0.001). The group diagnosed with PCa had higher PSA level and PSA density, as well as lower PV and VPC than that without PCa (p<0.001, p=0.001, p<0.001, p<0.001, respectively). Stratifying according to biopsy methods, MR-TBx was performed in 73 (4.6%), 12+2HLTBx in 120 (7.5%), sPBx in 75 (4.7%), extended biopsy in 212 (13.3%), and 12-core PBx in 1,118 (70.0%) cases. The CDRs of MR-TBx, 12+2HLTBx, sPBx, extended biopsy, and 12-core PBx were 43.8%, 40.8%, 34.7%, 33.0%, and 20.0%, respectively. There was a significant difference in CDRs among the biopsy methods (p<0.001). When comparing the characteristics according to the biopsy methods, significant differences were found in age, hypertension, body mass index, PSA, presence of biopsy history, VPC, number of total core, number of positive core, and the proportion of Gleason score ≥7 (3+4) among the biopsy methods (p=0.025, p=0.028, p=0.031, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001, p=0.037 respectively). In patients diagnosed with PCa, the ratios of positive core and total core for MR-TBx, 12+2HLTBx, sPBx, extended biopsy, and 12-core PBx were 35.7%, 24.6%, 27.6%, 30.2%, and 30.7%, respectively. Among the patients diagnosed with PCa, the proportions of Gleason score ≥7 (3+4) in MR-TBx, 12+2HLTBx, sPBx, extended biopsy, and 12-core PBx were 71.9%, 51.0%, 57.7%, 65.7%, and 48.6%, respectively.

For predicting the diagnosis of PCa, age (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.051–1.094; p<0.001), PSA (OR, 1.17; 95% CI, 1.078–1.269; p<0.001), PV (OR, 0.97; 95% CI, 0.951–0.997; p=0.031), PSA density (OR, 0.98; 95% CI, 0.967–1.000; p=0.052), VPC (OR, 1.01; 95% CI, 1.001–1.019; p=0.035), and number of total core (OR, 0.98; 95% CI, 0.972–0.988; p<0.001) were found to be significant in the univariate analyses (p<0.05). The optimal cut-off values were determined using Youden’s index (sensitivity+specificity-1). The optimal cut-off values were based on predefined values and according to a sensitivity analysis using Youden index. Statistical analyses were performed using the IBM SPSS Statistics version 23.0 for Windows (IBM Corp., Armonk, NY, USA). All tests were two-sided and performed at the 5% significance level.

Table 1. Basic patients’ characteristics

| Characteristic                  | MR-TBx | 12+2HLTBx | Saturation biopsy | Extended biopsy | 12-core PBx | p-value |
|--------------------------------|--------|-----------|-------------------|----------------|-------------|---------|
| No. of cases (total n=1,598)   | 73 (4.6)| 120 (7.5) | 75 (4.7)          | 212 (13.3)     | 1,118 (70.0)|         |
| Age (y)                        | 65.8±8.6| 65.9±8.6  | 66.2±10.3         | 64.8±8.0       | 63.6±8.6    | 0.025   |
| Hypertension                   | 19 (26.0)| 49 (40.8) | 17 (22.7)         | 55 (25.9)      | 323 (28.9)  | 0.028   |
| Diabetes mellitus              | 10 (13.7)| 10 (8.3)  | 9 (12.0)          | 28 (13.2)      | 188 (16.8)  | 0.091   |
| BMI (kg/m²)                    | 24.8±2.8| 24.6±2.9  | 24.8±4.5          | 24.5±2.8       | 27.5±3.1    | 0.018   |
| Biopsy history                 | 20 (27.4)| 14 (11.7) | 9 (12.0)          | 15 (7.1)       | 66 (5.9)    | <0.001  |
| PSA (ng/mL)                    | 6.2±2.2 | 5.5±1.7   | 5.8±1.9           | 5.8±2.1        | 5.8±2.1     | 0.031   |
| PV (cc)                        | 44.2±16.2| 41.6±15.0| 46.0±25.2         | 41.9±16.4      | 41.8±17.0   | 0.566   |
| PSA density (ng/mL/cc)         | 0.17±0.10| 0.16±0.08 | 0.16±0.10         | 0.16±0.09      | 0.16±0.10   | 0.857   |
| VPC (cc/core)                  | 2.9±1.3 | 3.0±1.1   | 1.9±1.1           | 3.0±1.2        | 3.5±1.4     | <0.001  |
| Number of total core           | 15.4±1.8| 14.0±0.0  | 24.0±0.0          | 14.4±1.6       | 12.0±0.0    | <0.001  |
| Number of positive core        | 2.6±4.4 | 1.4±2.5   | 2.3±4.4           | 1.5±2.9        | 0.7±1.9     | <0.001  |
| Diagnosis of prostate cancer   | 32 (43.8)| 49 (40.8) | 26 (34.7)         | 70 (33.0)      | 224 (20.0)  | <0.001  |
| Gleason score                  |         |           |                   |                |             | 0.037   |
| 6                              | 9/32 (28.1)| 24/49 (49.0)| 11/26 (42.3)     | 24/70 (34.3)   | 113/224 (50.4)|         |
| ≥7                             | 23/32 (71.9)| 25/49 (51.0)| 15/26 (57.7)     | 46/70 (65.7)   | 111/224 (49.6)|         |
| Period                         |         |           |                   |                |             | <0.001  |
| 2006–2010                      | 0 (0.0) | 0 (0.0)   | 0 (0.0)           | 62 (29.2)      | 604 (54.0)  |         |
| 2011–2015                      | 73 (100.0)| 120 (100.0)| 75 (100.0)       | 150 (70.8)     | 514 (46.0)  |         |

Values are presented as number (%) or mean±standard deviation.

MR-TBx, magnetic resonance imaging targeted biopsy; 12+2HLTBx, 12+2 hypoechoic lesion target biopsy; PBx, prostate biopsy; BMI, body mass index; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core.
Outcomes of several biopsy modalities in practice

We identified age (OR, 1.051; 95% CI, 1.034–1.069; p<0.001), PSA (OR, 1.074; 95% CI, 1.049–1.100; p=0.001), PV (OR, 1.050; 95% CI, 1.022–1.079; p=0.001), VPC (<3.0 cc/core) (OR, 2.37; 95% CI, 1.509–3.711; p<0.001), and biopsy methods (p=0.045) as significant factors in the multivariate analysis. In the biopsy methods, MR-TBx was superior to other protocols in cancer detection, but it was shown to have no significant difference with sPBx (OR, 0.46; 95% CI, 0.240–0.865; p=0.016; OR, 0.62; 95% CI, 0.266–1.462; p=0.277; respectively) (Table 2).

We also performed a sub-analysis according to the presence of biopsy history. For patients who underwent initial PBx, multivariate analysis reported that age (OR, 1.07; 95% CI, 1.048–1.088; p<0.001), PSA (OR, 1.24; 95% CI, 1.143–1.338; p<0.001), PV (OR, 0.97; 95% CI, 0.951–0.981; p<0.001), VPC (<3.0 cc/core) (OR, 2.21; 95% CI, 1.440–3.405; p<0.001), and biopsy methods (p=0.045) were identified as the significant factors in the multivariate analysis. Among the biopsy methods, sPBx was comparable to MR-TBx in terms of PCa diagnosis (p=0.478), whereas the other protocols have a significantly lower detection rate than MR-TBx (OR, 0.38; 95% CI, 0.197–0.772; p=0.007).

For patients with a biopsy history, age (OR, 1.11; 95% CI, 1.036–1.182; p=0.002) and VPC (<3.0 cc/core) (OR, 4.35; 95% CI, 1.621–12.791; p=0.004) were identified as the significant factors in the multivariate analysis. Notably, the biopsy methods were not found as significant factors in repeat biopsy (Table 3).

**DISCUSSION**

Age, PSA, and PV were considered as significant predictors of PCa diagnosis [9]. Among these variables, PSA had a major drawback, as it could be possibility affected by its lack of cancer specificity and the lack of a common upper or lower threshold value [10,11]. Developing a strategy for utilizing the clinical parameters that are routinely evaluated, VPC calculated by PV and the number of biopsy cores could be beneficial in terms of cost, time, and treatment de-

**Table 2. Univariate and multivariate logistic regression analyses predicting the presence of prostate cancer**

| Characteristic                  | Univariate | Multivariate |
|--------------------------------|------------|--------------|
|                                | OR (95% CI) p-value | OR (95% CI) p-value |
| Age*                           | 1.05 (1.038-1.069) <0.001 | 1.07 (1.051-1.094) <0.001 |
| Previous biopsy history         | 1.30 (0.867-1.940) 0.206 |               |
| PSA*                           | 1.17 (1.097-1.238) <0.001 | 1.17 (1.078-1.269) <0.001 |
| PV*                            | 0.96 (0.952-0.969) <0.001 | 0.97 (0.951-0.982) <0.001 |
| VPC <3.0 cc/core                | 3.38 (2.644-4.327) <0.001 | 2.37 (1.509-3.711) <0.001 |
| Biopsy methods                 | <0.001 | 0.045 |
| MR-TBx                         | Reference | Reference |
| Saturation biopsy              | 0.68 (0.350-1.320) 0.254 | 0.62 (0.266-1.462) 0.277 |
| Other protocols                | 0.40 (0.246-0.640) <0.001 | 0.46 (0.240-0.865) 0.016 |

OR, odds ratio; CI, confidence interval; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core; MR-TBx, magnetic resonance imaging targeted biopsy.

*Continuous variables.

**Table 3. Univariate and multivariate logistic regression analyses for predicting the presence of prostate cancer according to biopsy history**

| Characteristic                  | Initial biopsy | Repeat biopsy |
|--------------------------------|---------------|---------------|
|                                | Univariate OR (95% CI) p-value | Multivariate OR (95% CI) p-value | Univariate OR (95% CI) p-value | Multivariate OR (95% CI) p-value |
| Age*                           | 1.05 (1.037-1.069) <0.001 | 1.07 (1.048-1.088) <0.001 | 1.06 (1.004-1.114) 0.035 | 1.11 (1.036-1.182) 0.002 |
| PSA*                           | 1.19 (1.114-1.266) <0.001 | 1.24 (1.143-1.338) <0.001 | 0.97 (0.800-1.168) 0.725 |               |
| PV*                            | 0.96 (0.950-0.969) <0.001 | 0.97 (0.951-0.981) <0.001 | 0.97 (0.939-0.996) 0.027 | 1.03 (0.939-1.125) 0.547 |
| VPC <3.0 cc/core               | 3.36 (2.600-4.349) <0.001 | 2.21 (1.440-3.405) <0.001 | 3.49 (1.476-8.256) 0.004 | 4.55 (1.621-12.791) 0.004 |
| Biopsy methods                 |               |               | 0.001 | 0.007 |
| MR-TBx                         | Reference     | Reference     | Reference | Reference |
| Saturation biopsy              | 0.68 (0.350-1.320) 0.254 | 0.62 (0.266-1.462) 0.277 |               |               |
| Other protocols                | 0.40 (0.246-0.640) <0.001 | 0.46 (0.240-0.865) 0.016 |               |               |

OR, odds ratio; CI, confidence interval; PSA, prostate-cancer specific antigen; PV, prostate volume; VPC, volume per core; MR-TBx, magnetic resonance imaging targeted biopsy.

*Continuous variables.
cision making. After introducing VPC, several studies have investigated the relationship between PV and the number of biopsy cores [9,12-14]. Finally, VPC was an even stronger independent predictor of biopsy results than PV [9].

A direct relationship showing higher CDR for lower VPC supports the idea that adequately sampling the prostate is critical in avoiding low CDR. Vashi et al. [12] developed a mathematical model to calculate the number of biopsy cores that considered age, PV, tumor volume, and doubling time. Remzi et al. [13] suggested the Vienna nomogram to determine the number of cores based on age and PV in patients with PSA values of 2 to 10 ng/mL. The increased number of biopsy cores was considered to possibly result in greater discomfort and more complications for the patient. Therefore, the optimal cut-off value of 4.0 was suggested for high CDR without taking an excessive number of biopsy specimens in patients with PSA <20 ng/mL [9]. In this study, the cut-off value of VPC (30 cc/core) was obtained by AUC of the ROC curve for patients with PSA <100 ng/mL.

MRI before PBx in patients who had undergone an initial biopsy improved the diagnostic yield of clinically significant cancer by reducing unnecessary PBx [15]. This study also supports the usefulness of prebiopsy MRI by confirming the high CDR of MR-TBx in the initial biopsy. The American Urological Association consensus statement on the recommendation to consider MRI for patients with negative results in prior PBx was made to improve CDR [16]. However, interestingly, this study reported that biopsy methods at repeat biopsy were not identified as significant factors. We assumed that this was due to the fact that MRI is only a tool used to increase the diagnostic rate of clinically significant PCa, not to increase the detection rate of insignificant PCa [17]. In particular, mimicking lesion may exist in MRI due to chronic prostatitis or other reasons such as previous PBx procedure. Therefore, these mimicking lesions may decrease the accuracy of diagnosing PCa. We considered that biomarkers are useful for discriminating these patients with mimicking lesions to appropriately identify patients who will undergo PBx. Second, VPC, instead of biopsy methods, was identified as a significant factor to predict PCa in patients with repeat biopsy. Notably, this result does not imply that MRI has no efficacy for patients with repeat biopsy, but our data indicate that proper core number should be adjusted using VPC, especially for cases with barrier to use of MRI.

Generally, sPBx is believed to result in higher CDR [18]. There was no significant difference in the complications between sPBx and standard biopsy [19]. In our study, the CDR of sPBx is compatible to that of MR-TBx. However, since sPBx requires more needle stapling, it is not suitable for office use considering pain or discomfort [20]. Especially, as the number of needles increased, tolerability of patients decreased. Thus, sPBx was performed only under general anesthesia, not local anesthesia.

This study evaluated the CDRs according to several biopsy methods in patients with PSA <10.0 ng/mL. In general, 30% to 35% of men with a PSA level of 4 to 10 ng/mL are diagnosed with PCa [6]. In this cohort with a median PSA of 5.41 ng/mL, the CDR of 25.1% was relatively lower than those in the previous studies. For 12-core PBx being the standard diagnostic method, the CDR of 20.0% was reported. These results could be related to several reasons. First, the detection rate in our cohort may differ from those in other studies performed by experts. Our institution's training program recommended the policy that most PBx procedures, excluding MR-TBx, sPBx and 12+HLTBx, should be performed by residents. Long periods of observation were required for the operator to achieve mastery in skills at a level sufficient for independent practice [21,22]. Second, although prebiopsy MRI was performed to reduce the number of cases with unfortunately missed PCa diagnosis, the MR-TBx protocol in our institution utilized the cognitive technique.

In NCCN, if MRI is available, MRI-guided biopsy is recommended using the MRI/ultrasonography fusion biopsy [6]. Nevertheless, this study reaffirmed that CDR of MR-TBx was higher than those of other PBx methods, which are generally used in practice. However, MRI and biomarker required additional cost. Furthermore, the costs of MRI and biomarkers are not reimbursed by the insurance before PCa diagnosis in Korea.

Complications including hematuria, infection, lower urinary tract symptoms, and pain occurred after PBx. Hospitalization for the management of serious biopsy-related adverse events was required in a minority of patients because of massive hematuria (<1%), febrile urinary tract infection or sepsis (0%–6.3%), and acute urinary retention (0.2%–1.7%), which are related to the increasing number of sampling cores [23]. To the best of our knowledge, there were no previous studies that have directly compared the complication rate among biopsy methods including MR-TBx, sPBx, extended biopsy, and 12-core PBx. In our cohort, cancer detection of sPBx was comparable to that of MR-TBx. However, MR-TBx showed a higher ratio of the number of positive cores to that of the total cores (37.1% vs. 27.5%) and proportion of significant cancer (Gleason score ≥7 [3+4] (71.9% vs. 57.7%) than sPBx. Furthermore, considering the direct relationship of complications and increasing number of biopsy cores, our findings will help clinicians decide the use of...
either MR-TBx or sPBx in clinical setting.

This study has some limitations. First, there were no obvious criteria for selecting the biopsy methods. Moreover, multiple physicians as biopsy operators performed PBx, which could account for the heterogeneity in the results. However, this demonstrates that an average group of urologists can achieve good PBx results in clinical practice. Second, analysis of the Prostate Imaging Reporting and Data System (PI-RADS) and CDR was not applied in this study. In patients who underwent biopsy before PI-RADS, MRI readings could not be converted back to PI-RADS in this retrospective analysis. Moreover, since the version of PI-RADS has changed during the study period, there was a concern that the results could be inconsistent. Third, although complications and CDR might be the considerable factors for choosing the appropriate biopsy method, this study did not analyze complications. Nevertheless, to the best of our knowledge, this study is the first to compare the various methods of PBx simultaneously.

CONCLUSIONS

This study reaffirmed the efficacy of MR-TBx on CDR in real-world practice. In cases with barriers to performing MRI, VPC might be useful for adjusting the optimal number of biopsy cores in repeat biopsy.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

AUTHORS’ CONTRIBUTIONS

Research conception and design: Kwang Suk Lee. Data analysis and interpretation: Kyo Chul Koo, Byung Ha Chung, and Kwang Suk Lee. Drafting of the manuscript: Kyung Tak Oh and Kwang Suk Lee. Approval of the final manuscript: all authors.

REFERENCES

1. Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66-70.
2. Carroll PR, Parsons JK, Andriole G, Bahnsen RR, Castle EP, Catalona WJ, et al. NCCN Guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw 2016;14:509-19.
3. Nazir B. Pain during transrectal ultrasound-guided prostate biopsy and the role of periprostatic nerve block: what radiologists should know. Korean J Radiol 2014;15:543-53.
4. Aigner F, Schäfer G, Steiner E, Jaschke W, Horninger W, Herrmann TR, et al. Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis. World J Urol 2012;30:341-6.
5. Kretschmer A, Tilki D. Biomarkers in prostate cancer - current clinical utility and future perspectives. Crit Rev Oncol Hematol 2017;120:180-93.
6. Carroll PH, Mohler JL. NCCN Guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw 2018;16:620-3.
7. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
8. Lee KS, Koo KC, Chung BH. Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study. World J Urol 2018;36:1059-65.
9. Jiang J, Colli J, El-Galley R. A simple method for estimating the optimum number of prostate biopsy cores needed to maintain high cancer detection rates while minimizing unnecessary biopsy sampling. J Endourol 2010;24:143-7.
10. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 2012;30:3020-5.
11. Avery KN, Metcalfe C, Vedhara K, Lane JA, Davis M, Neal DE, et al. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. Eur Urol 2012;62:649-55.
12. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998;159:920-4.
13. Remzi M, Fong YK, Dobrovits M, Anagnostou T, Seitz C, Waldert M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174:1256-60; discussion 1260-1; author reply 1261.
14. Letran JL, Meyer GE, Loberiza FR, Brawer MK. The effect of prostate volume on the yield of needle biopsy. J Urol 1998;160:1718-21.
15. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815-22.
16. Kim EH, Andriole GL. Improved biopsy efficiency with MR/ultrasound fusion-guided prostate biopsy. J Natl Cancer Inst 2016;108:djw040.
17. Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ. PI-RADS version 2: a pictorial update. Radiographics
2016;36:1354-72.
18. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011;186:850-4.
19. Jiang X, Zhu S, Feng G, Zhang Z, Li C, Li H, et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis. Eur Urol 2013;63:1031-9.
20. Lee C, Woo HH. Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy--a systematic review. BJU Int 2014;113 Suppl 2:48-56.
21. Benchikh El Fegoun A, El Atat R, Choudat L, El Helou E, Hermieu JF, Dominique S, et al. The learning curve of transrectal ultrasound-guided prostate biopsies: implications for training programs. Urology 2013;81:12-5.
22. Lawrentschuk N, Toi A, Lockwood GA, Evans A, Finelli A, O’Malley M, et al. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol 2009;182:2659-63.
23. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.